Current standard treatments for advanced HCC include tyrosine kinase inhibitors (TKIs) and a combination of atezolizumab and bevacizumab, an immune checkpoint inhibitor (ICI) and a monoclonal antibody against vascular endothelial growth factor (VEGF), respectively. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.